#Investment #Jordan #Amman #MS Pharma #Olayan Financing

MS Pharma and Olayan Financing Company: A Strategic Partnership for Growth

On May 18, 2026, MS Pharma made headlines with the announcement of a strategic investment from Olayan Financing Company (OFC). This transformative partnership is set to catalyze MS Pharma's growth trajectory in Saudi Arabia and the wider MENA region, reaffirming the company's commitment to innovation and long-term value creation.

Investment Details

The collaboration commenced with OFC acquiring a minority stake in MS Pharma through a significant cash investment. This transaction not only solidifies MS Pharma's financial footing but also enhances its capabilities to implement ambitious growth plans across the MENA region. The funds will particularly support the expansion of MS Pharma's biosimilars portfolio, strengthen manufacturing capabilities, and ensure supply chain resilience to better serve patients and healthcare providers.

The signing ceremony marked a momentous occasion for both companies, with leaders from MS Pharma and Olayan addressing the significant strategic implications of their collaboration. Ghiath Sukhtian, Chairman of MS Pharma, expressed enthusiasm over Olayan's involvement, stating, “We are excited and honored to welcome OFC as a partner. Their global expertise and strong roots in Saudi Arabia will contribute significantly to our objectives.” Furthermore, he emphasized the importance of the dedicated efforts of MS Pharma's team in establishing the company as a prominent player in the pharmaceutical industry.

CEO Kalle Kaend also shared his insights on the partnership, mentioning, “This investment comes at an exciting turning point for MS Pharma, enabling us to deepen our expertise in biologics and expand our MENA presence.” He recognized the value Olayan brings to the table with its established network in Saudi Arabia, which will be instrumental in achieving MS Pharma's ambitious goals.

Strategic Alignment

Nabeel Al-Amudi, CEO of Olayan Financing Company, spoke about the partnership's relevance, highlighting MS Pharma's leadership in the pharmaceutical sector, particularly regarding generics and biologics. He stated, “We are pleased to partner with MS Pharma at this stage in its growth, and we look forward to supporting its ongoing expansion throughout Saudi Arabia and the MENA region.” This pledge aligns with OFC's long-term investment strategy, aiming for meaningful partnerships that foster regional economic development.

A key element of this partnership is MS Pharma’s existing leadership in the biosimilars market. In Saudi Arabia, the company’s manufacturing facility for biologics was the first in the Kingdom to receive Good Manufacturing Practices (GMP) certification from the Saudi Food and Drug Authority (SFDA). This positions MS Pharma to become a primary local supplier of biologic products by scaling up quality therapies in line with Saudi Arabia's biotechnology strategy and Vision 2030 objectives.

Future Prospects

As MS Pharma moves forward, the company aims to not only strengthen local manufacturing but also collaborate more deeply with global partners for development and licensing. The strategic focus will be on leveraging their manufacturing capabilities to meet international export demands, thus enhancing the overall access to high-quality medicines across markets.

In summary, this strategic partnership with Olayan Financing Company marks a significant milestone for MS Pharma as it embarks on its next growth phase. With enhanced resources and an expanded network, MS Pharma is well-positioned to reinforce its leadership in the pharmaceutical sector and contribute significantly to the health and wellbeing of patients in the MENA region.

For more information on MS Pharma, please visit www.mspharma.com.